Piper Sandler Initiates Coverage On Bio-Techne with Neutral Rating, Announces Price Target of $65
Benzinga Newsdesk 4 months ago
NewsPrice TargetInitiationAnalyst Ratings
Piper Sandler analyst David Westenberg initiates coverage on Bio-Techne (NASDAQ:TECH) with a Neutral rating and announces Price Target of $65.
Piper Sandler analyst David Westenberg initiates coverage on Bio-Techne (NASDAQ:TECH) with a Neutral rating and announces Price Target of $65.